Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria :~* Participants with Type 1 diabetes mellitus~Exclusion criteria:~* HbA1c greater than (\>) 9% (at screening)~* Participants receiving \>0.5 U/kg body weight basal insulin in the last 30 days prior to screening visit~* Participants not on stable insulin dose (+/- 20% total basal insulin dose) in the last 30 days prior to screening visit~* Less than 1 year on any basal plus mealtime insulin~* Participants using pre-mix insulins, human regular insulin as mealtime insulin and/or any antidiabetic drugs other than basal insulin and mealtime analogue insulin in the last 3 months before screening visit~* Use of an insulin pump in the last 6 months before screening visit;~* Any contraindication to use of insulin glargine as defined in the national product label~* Not willing to inject insulin glargine as assigned by the randomization process once daily in the morning or evening~* Hospitalization for diabetic ketoacidosis or history of severe hypoglycemia (requiring 3rd party assistance) in the last 6 months prior to randomization~* Initiation of any glucose-lowering agents in the last 3 months before screening visit~* Weight change of greater than equal to (\>=) 5 kg during the last 3 months prior to screening visit~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require laser, surgical treatment or injectable drugs during the study period~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- HOE901-U300 Morning Then Evening (Type: EXPERIMENTAL): HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
- HOE901-U300 Evening Then Morning (Type: EXPERIMENTAL): HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
- Lantus Morning Then Evening (Type: ACTIVE_COMPARATOR): Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
- Lantus Evening Then Morning (Type: ACTIVE_COMPARATOR): Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.

Based on this trial design, predict the completion outcome and termination type (if applicable).